GB2040917A - Octahydro-2h - pyrrolo (3,4-g) quinolines - Google Patents

Octahydro-2h - pyrrolo (3,4-g) quinolines Download PDF

Info

Publication number
GB2040917A
GB2040917A GB7922532A GB7922532A GB2040917A GB 2040917 A GB2040917 A GB 2040917A GB 7922532 A GB7922532 A GB 7922532A GB 7922532 A GB7922532 A GB 7922532A GB 2040917 A GB2040917 A GB 2040917A
Authority
GB
United Kingdom
Prior art keywords
alkyl
trans
compound
quinoline
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB7922532A
Other versions
GB2040917B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/031,642 external-priority patent/US4235909A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of GB2040917A publication Critical patent/GB2040917A/en
Application granted granted Critical
Publication of GB2040917B publication Critical patent/GB2040917B/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

1
GB 2 040 917 A
1
SPECIFICATION
Octahydro-2H-pyrrolo [3,4-g] quinolines
5 This invention provides 5- and 7 - substituted -4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinolines of the following structure
10
'•w*\ /S\
*■4 I !"'!
wherein 15 R1 is H orCrC3 alkyl;
R2 is CrQ) alkyl or ally);
R3 is H or CH2X wherein X is CN, CONH2, S02CH3, SCH3 or OCH3; and the pharmaceutically-acceptable acid addition 20 salts thereof.
The compounds of formula I can be prepared by reacting a compound of the formula
25
30
R3 I
A*-
O jy.
Id r -J ... .•■«( [ f- -i
4jf -Mf
65 la lb
In addition, introduction of a substituent atC-7 (R3 is other than H) creats a new chiral center and the compounds of that structure exists as 4 stereoisomers in two racemic pairs. The synthetic procedures to 70 be set forth herein yield a single predominant race-mate consisting of the4a/3,7j8,8aa isomer and its mirror image, the 4aa, 7a, 8a/3 isomer. Resolution of this racemate into its component diastereoisomers can be readily accomplished by methods currently 75 available in the art. Regardless of the structure currently assigned to a given isomer or racemate, this invention provides compounds of the above formula having dopaminergic activity, whether in pure form as a single diastereoisomer or admixed with one, or 80 more, less active or even inactive diastereoisomers.
Also within the scope of this invention are novel intermediates of the formula
85
90
wherein R1 is (CrCaJalkyl-CO;
R2 is H, CrC3 alkyl, or allyl;
35 R3 is H orCH2V;
Y is CI, Br, 0S02phenyl, O-tosyl, or SO^CrQjlalkyl; with base to provide the compounds of formula I wherein R1 isH;
optionally followed by reacting with an afkyl halide 40 to obtain the compounds of formula I where R1 is C1-C3 alkyl;
where R2 is H followed by reacting with an alkyl or allyl halide or reductive alkylation with an appropriate aldehyde and metal hydride to obtain the com-45 pounds of formula I wherein R2 is C,-C3 alkyl or allyl; followed by reacting the compound of formula Id where R3 is CH2Y with sodium methylate, methyl-mercaptan sodium salt, sodium cyanide, sodium methanesulfinate, to obtain the compounds of for-50 mula I where R3 is CH2X where X is CN, SCH3,
S02CH3, or OCH3; and optionally followed by hydration of the compounds of formula I where R3 is CH2CN to obtain the compounds of formula I where R3 is CH2CONH2. 55 In the above formula, the ring junction (the 4a, 8a bond) is trans and the compounds are obtained as a racemic pair. The two stereoisomers constituting the racemate can be drawn as structures la and lb below
60 . . H .
A^'V/'X /■
R1-N"
/\ A>
U
/
lc wherein R1 is H or(CrC3)alkyl-CO;
R2 is H, benzyl or C,-C3 alkyl; and 95 R3 is H, COOfCTQOalkyl, COOH, or CH2X1 wherein X1 is OH, CI, OSO^CrC^alkyl, OS02toly[, or 0S02phenyl;
with the proviso that both R1 and R3 can not be H when R2 is C,-C3 alkyl; and 100 their salts.
In the above formulas, the term "C-i-C3 alkyl", includes methyl, ethyl, n-propyl and isopropyl.
The pharmaceutically-acceptable acid addition salts of this invention include salts derived from 105 inorganic acids such as: hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodic acid, nitrous acid, phosphoric acid and the like, as well as salts derived from nontoxic organic acids such as aliphatic mono and dicarbox-110 ylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic and alkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acid. Such phar-maceutically - acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phos-115 phate, monohydrogenphosphate, dihydrogen-phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobuty-rate, caprate, heptanoate, propiolate, oxalate, malo-120 nate, succinate, suberate, sebacate, fumarate, male-ate, mandelate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzo-ate, phthalate, terephthalate, benzenesulfonate, 125 toluenesulfonate, chlorobenzenesulfonate,
xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, /3-hydroxybutyrate, glycollate, malate, tartrate, methansulfonate, prop-anesulfonate, naphthalene -1 - sulfonate, naph-130 thalene - 2 - sulfonate and the like salts.
2
GB 2 040 917 A
2
The intermediates coming within the scope of Formula I from useful salts with all varieties of acids, not just non-toxic acids, and these salts are used for reaction and purification purposes.
Illustrative compounds falling within the scope of formula I include:
trans - dl - 2,5 - dimethyl - 7 - methylmercap-tomethyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline sulfate trans - dl - 2,5 - dimethyl - 7 - methoxymethyl -4,4a,5,6,7,8,8a,9 - octahydro - 2H pyrrolo [3,4-g] quinoline sulfate trans - dl - 5 - methyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline hydrochloride trans - dl - 5 - isopropyl - 4,4a,5,6,7,8,8a,9 -octahydro - 2H - pyrrolo [3,4-g] quinoline trans - dl - 2 - methyl - 5 - n - propyl - 7 - methyl-sulfonyimethyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H -pyrrolo [3,4-g] quinoline maleate trans - dl - 5 - ethyl - 4,4a,5,6,7,8,8a,9 - octahydro -2H- pyrrolo [3,4-g] quinoline trans - dl - 5 - allyl - 4,4a,5,6,7,8,8a,9 - octahydro -2H - pyrrolo [3,4-g] quinoline.
The compounds of formula I in which R3 is H are 25 prepared according to the procedure outlines in Reaction Scheme I below. In Reaction Scheme I, only one stereoisomer has been drawn for convenience, but it should be remembered that each decahydro-quinoline and each octohydropyrrolo [3,4-g] 30 quinoline exists as a racemate. In addition, R2 is otherthanH.
10
15
20
70
75
"O
CHaCO
IX
I v*
/y
Reaction Scheme I
35
40
45
50
55
60
65
/
pyrroltdine acid catalyst acrylamide v\A
III H
VV
V R*
L
v\A
HCI
NaCNBHs
/\5/\
w yy\T
\4\/
VII I
(CH3)sNCH(0Z")a
(CHaCO) 20
K glycinate
YYxi
(OtsliNo/
In the above reaction scheme, Z-CO is an acyl protecting group in which Z is (Ci-C3)alkylr (C2-C3)alkenyl, (C2-C3)alkynyl, (C5-C6)cycloalkyl, phenyl or substituted phenyl wherein the substituting group can be methyl, methoxy, chloro and the like, at any 80 position of the phenyl ring. Illustratively, Z-CO can be acetyl, propionyl, butyryl, propiolyl, acrylyl, benzoyl, p-toluyl, o-chlorobenzoyl, or m-methoxybenzoyl.
Acetals of dimethylformamide useful in producing 85 compound VIII in Reaction Scheme I (and compound XV in Reaction Scheme II below) have the general formula (CH3)2N - CH - (OZ")2 in which Z" is (C,-C8)alkyl, (C5-C6)cycloalkyl, (C3-C4)alkenyl, (C3-C4)alkynyl and the like. We preferto employ one of 90 the commercially available acetals of dimethylformamide; i.e.; the dimethyl, diethyl, diisopropyl, dibutyl, dicyclohexyl, dipropyl or dineopentyl acetals.
In accordance with Reaction Scheme 1,4- acylox-95 ycyclohexanone (II) prepared by the procedure of E.R.H. Jones and F. Sondheimer,./. Chem. Soc., 615, (1949) is reacted with pyrrolidine in the presence of an acid catalyst to yield a pyrrolidine enamine. This enamine is in turn reacted with acrylamideto pro-100 duce a mixture of dl - 6 - acyloxy- 3,4,5,6,7,8 -
hexahydro - 2(1 H) - quinolinone and dl - 6 - acyloxy -3,4,4a,5,6,7 - hexahydro - 2(1 H) - quinolinone represented by formula ill, the dotted lines indicating the alternative positions of the double bond. 105 Next, the acidic nitrogen (acidic since it is alpha to a carbonyl group) is alkylated with an alkyl halide R2X wherein R2 has the same meaning as hereinabove and X is a halogen such as CI, Br or I, in the presence of sodium hydride to yield a mixture of 110 dl -1 - (CrC3) alkyl or allyl or benzyl) -6 - acyloxy-3,4,5,6,7,8 - hexahydro - 2(1 H) - quinolinone and its A8 isomer (IV). Reduction of this amide with lithium aluminum hydride or other suitable organometaliic reducing agent yields a mixture of dl -1 - (CrC3) alkyl 115 (or allyl or benzyl) - 6 - hydroxy -1,2,3,4,5,6,7,8 -
octahydroquinoline and its As isomer. In this reaction mixture, conditions are encountered which serve to hydrogenolyze the acyloxy group to a hydroxyl * group at C-6. The dl -1 - (Cn-C3) - alkyl (or allyl or 120 benzyl) - 6 - hydroxyoctahydroquinoline mixture is next converted to an ammonium salt by treatment with hydrochloric acid, and the ammonium salt is then reduced with sodium cyanoborohydrideto yield trans - dl -1 - (CtC3) alkyl (or allyl or benzyl) - 6 125 hydroxydechydroquinoline (VI). Next, the trans - dl -1 - (C,-C3 alkyl, allyl, or benzyl) - 6 -hydroxydecahydroquinoline (VI) is oxidized using, preferably, chromium trioxide in acetic acid, to yield the corresponding 6-oxo compound (VII). By adapt-130 ing the procedure of Zav'yalof et al. C.A., 80,59815z
3
GB 2 040 917 A
3
(1974), lzv,Akad. Nauk, SSSR. Ser. Khim 2527-7 (1973), this 6-oxo compound (VII) is reacted with dimethylformamide dimethylacetal to yield a 7 -dimethylaminomethylene - 6 - oxo - derivative (VIII).
5 Reaction of this derivative with potassium glycinate followed by treatment of the thus formed intermediate product with acetic anhydride yields a tricyclic derivative, trans - dl - 2 - acetyl - 5 - [(C,-C3) alkyl, allyl or benzyl)! - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyr-10 role[3,4-g] quinoline (IX). Removal of the acetyl group at N-2 with base yields the dopamine agonist (X) when Rz is (C,-C3)alkyl or allyl, or a useful intermediate when R2 is benzyl.
Those compounds in which R1 is CrC3 alkyl are 15 prepared from compound X by taking advantage of the acidic hydrogen in the pyrrole ring and reacting an anionic salt thereof, prepared from sodium hydride or other suitable base, with an alkyl halide, R1 X where R1 is (C-,-C3) alkyl or allyl and X is CI, Br or I. 20 Those compounds in which R2 is benzyl can be transformed into compounds in which R2 is (C1: C3)alkyl or allyl as follows: the benzyl group can be removed by reductive cleavage or by treatment with cyanogen bromide to yield, eventually, a compound 25 in which R2 is H. The usual conditions for removing an N-benzyl group are hydrogen with a palladium -on - carbon catalyst or reaction with cyanogen bromide followed by reductive (Zn and acetic acid) cleavage of the N-cyano compound. This debenzy-30 lated compound can then be alkylated with an allyl or a lower alkyl halide, or alternatively it may be reductively alkylated using acetaldehyde, propional-dehyde or other aldehyde with a metal hydride, such as sodium cyanoborohydride.
35 Compounds according to formula I above in which R3 is other than H are prepared according to a slightly different, but comparable, synthetic route illustrated in Reaction Scheme II below. As in Reaction Scheme I, the synthetic procedure is illustrated 40 for convenience with respect to a single stereoisomer (referring to the bridgehead configuration) the 4a /3,8aa isomer.
Reaction Scheme II
0 II
A
R NHs
\
\ /
CH2=C-C00Z' / i
I CHzHaI
o-co-z
Y V ~vcooz' VV
I
XI R
/•w\
acid bh4~
•f-C00Z'
'Y
R2
/ Z'OH / OH \ HCl \
\ / W \
vi f-C00Z'
>Y
pyrid!ne*HCl CrOs
H
0=7' Y XJ-C00Z'
w
(CH3)aNCH(0Z")g S
0=f » VC00Z' (CH3)2NCH=i. ,f. ,•
'A*
K glycinate acetic anhydride
\l/
H
/ hydrolysis AcN^
<3,y
CH=f f VcOOZ'
H< I
0H=viv-
wherein Z and Z" have the same significance as in Reaction Scheme I, Hal is chloro or bromo and Z' is 45 part of a readily hydrolyzable group Z'O-CO including (CrC2)alkyl, phenyl substituted (C^QJalkyl, illustratively benzyl, phenethyl, p-methoxybenzyl,
methyl, ethyl and others.
In accordance with the Reaction Scheme II, a 4 -50 acyloxycyclohexanone (II) is reacted with an a -halomethylacrylate ester, for illustrative purposes, the ethyl ester, and an amine, RNH2, wherein R is C,-C3 alkyl, allyl or benzyl. The product of this reaction is a mixture of dl -1 - substituted - 3 - ethoxycar-55 bonyl - 6 - acyloxy -1,2,3,4,5,6,7,8 - octa hydro-
quinoline and dl -1 - substituted - 3 - ethoxycarbonyl -6- acyloxy - 1,2,3,4,4a,5,6,7 - octahydroquinoline represented by XI in which the dotted line indicates the alternate positions of the double bond. The hyd-60 rochloride salts of these isomers are prepared and the resulting mixture reduced with sodium cyanoborohydride to yield trans - dl -1 - substituted -3 - ethoxycarbonyl - 6 - acyloxydechydroquinoline (XII). Hydrolysis of this diesterto yield a 6 - hydroxy-65 3 - carboxylic acid followed by reesterification of the carboxylic acid group with ethanol or other alcohol in the presence of acid yields trans - dl -1 - substituted - 3 - ethoxycarbonyl - 6 - hydroxydecahydro-quinoline (XIII). Oxidation of the hydroxy group with 70 Sarett's Reagent (pyridine hydrochloride and chromium trioxide) produces the corresponding 6-oxo compound (XIV). Treatment of this 6-oxo derivative with dimethylformamide dimethylacetal results in reaction at C-7 (adjacent to the keto group) 75 to give trans - dl -1 substituted - 3 - ethoxycarbonyl -
4
GB 2 040 917 A
4
6 - oxo - 7 - (dimethylaminomethylene) decahydro-quinoline (XV). Reaction of this derivative with potassium glycinate followed by a treatment of the intermediate product with acetic anhydride gives the 5 tricyclic derivative, trans - dl - 2 - acetyl - 5 - substituted - 7 - ethoxycarbonyl - 4,4a,5,6,7,8,8a,9 -octahydro - 2H - pyrrolo [3,4-g] quinoline (XVI). Hydrolysis with sodium ethoxide in ethanol yields the NH compound (XVII).
10 The octahydropyrrolo [3,4-g] quinoline of Formula XVI represents a single isomer. The mirror image of XVI is produced concomitantly and is included within the scope of this invention. We believe, based upon analogy with the D-ergolines, that the dias-15 tereoisomer XVI as drawn is the isomer having dopamine agonist activity. The trans - dl - racemate, which contains XVI and its mirror image, is of course useful as a dopamine agonist, even though most of the desired activity resides in one of its component 20 stereoisomers.
Compounds according to XVI above in which R2 is methyl or benzyl can be transformed into compounds in which R2 is ethyl, allyl or n-propyl by reaction with cyanogen bromide. The intermediate 25 5-cyano derivative can be reductively cleaved (zinc plus acetic acid) to yield a compound in which R2 is H. In addition, the benzyl group can be removed by hydrogenation with palladium - on - carbon to yield those intermediates in which RZ=H. Alkylation of 30 those compounds in which R2 is H can be accomplished by reaction with an alkyl halide, R2CI, R2Br or R2I. Alternatively, the secondary amine can be reacted with acetadehyde, acrolein, or propional-dehyde under reducing conditions (NaBH3CN) to 35 yield an N-ethyl, N-allyl or N-n-propyl derivative.
The dopamine agonists of formula I in which R3 is other than H; i.e. those compounds in which R3 is CH2X wherein X is CN, OCH3, SCH3, S02CH3 or CO-NH2, are prepared according to Reaction Scheme 40 III below
Reaction Scheme III
xCH=f
"SJ
H
vLr
CH=f
I
tosy!-Cf (Ci-Cj)alkyl-SOaCf phenyl-S02CI
SOCIz PC Is POCIa PBr3
H\
ay r
i
R
NaCN CH3SN3 CHaONa CHsSOsNa
wherein Z' and R have the same significance as before, Y is a "leaving" group: CI, Br, 0S02phenyl, O-tosyl orS02(C1-C3)alkyl, R2 is H, S02phenyl, tosyl or S02(CrC3)alkyl, and X is CN, SCH3, OCH3 or 45 S02CH3. The acetyl group of a compound according to XVI in Reaction Scheme II is hydrolyzed with sodium ethoxide in ethanol or sodium methoxide in methanol to yield a desacetyl derivative. The car-boalkoxy group is then reduced with a metal hydride 50 such as LiAIH4to an hydroxymethyl group, thus providing a trans - dl - 5 - substituted - 7 - hydroxmethyl -4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrole [3,4-g] quinoline (XVIII). The hydroxyl can be replaced with a chlorine or bromine leaving group and the result-55 ing chloromethyl or bromomethyl compound reacted with NaCN to yield a compound in which R3 is CH2-CN. Other leaving groups—groups readily replaced by a nucleophilic reagent—such as the mesyloxy, p-tosyloxy, benzenesulfonyloxy and the 60 like groups [when X in formula I, la or lb or Yin formula XIX, is OSO^CrCaJaikyl, 0S02phenyl or OS02tolyl] can be produced by acylation of the hydroxy group with a sulfonyl halide. Reaction of the thus-produced compound with sodium methylate, * 65 methylmercaptan sodium salt, sodium cyanide, sodium methansulfinate or other basic salts of methanol, methylmercaptan yields compounds * according to formula I, la or lb in which R3 is CH2X and X is SCH3,0CH3, CN or S02CH3. Compounds in 70 which X is C0NH2 are prepared by hydration of the corresponding cyano compound.
Compounds represented by formulas I, la and lb, in which R2 is H and by formulas IX, and X above have two centers of assymetry, the ring junction car-75 bons at8a and 4a. Thus, the compounds can occur
5
GB 2 040 917 A
5
as two racemates, ordinarily denominated as the trans-dl racemate and the cis-dl racemate. It is believed, however, according to the best evidence from 13C NMR spectral data of the maleatesaltofthe 5 compound according to Formula X above wherein R2 is benzyl, that the cyanoborohydride reduction (going from V to VI in Reaction Scheme I) yields a transfused decahydroquinoline. While the arguments for the trans configuration based upon 13C 10 NMR spectral data are compelling, an X-ray crystal-lographic investigation has also been carried out on the nicely crystalline enaminoketone (VIII) in which R2 is methyl, the precursor of the pyrrole (X). This X-ray analysis indicated clearly that the ring junction 15 is trans. Thus, onlythe trans racemate is prepared by the synthetic procedures disclosed herein and the compounds of formula I are preferably represented as the trans-dl steroisomers la and lb above in which R3 is H. Resolution of this racemate into its optical 20 antipodes can be accomplished by procedures known to those skilled in the art, and the individual trans-d and trans-l isomers are included within the scope of this invention.
When R3 is other than H, a third chiral center is 25 introduced at C-7, thereby doubling, at least in theory, the number of isomers produced by Reaction Schemes II and III. However, it is presently believed that the configuration of the C-7 group is "trans" to that of the 8a hydrogen. Thus in la above, R3 when it 30 is other than H, has a beta configuration with the 8a hydrogen having an alpha configuration. In the mirror image lb, the 8a hydrogen is beta and the C-7 substituent alpha. Thus the dl - trans - 7 substituted octahydropyrrolo [3,4-g] quinolines of formula I are 35 provided substantially as a single racemate.
In addition, it is apparent from an inspection of the dl - trans -1 - (substituted) - 6 - keto decahydroquinoline (VII) that reaction with dimethylformamide dimethylacetal could take place at either C-5 or C-7 40 since both these carbons are ortho to the ketone group and are thus "activated". The same X-ray crystallographic analysis of the enamine (VIII) clearly indicated that reaction had taken place at C-7 rather than C-5. Hence, the final tricyclic compounds IX, X, 45 XVI and I are the linear pyrrolo [3,4-g] quinolines rather than the angular tricyclic compounds (which would be named as 4,4a,5,6,7,8,8a,9 - octahydro - 1H -pyrrolo [2,3-i] quinolines).
This invention is further illustrated by the follow-50 ing specific examples.
STARTING MATERIALS Example A
Preparation of trans - dl - 2 - Acetyl - 5 - methyl -55 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline.
4 A reaction mixture was prepared from 52 g. of 4 -benzoyloxycyclohexanone, 30 ml. of pyrrolidine, a few crystals of p-toluene sulfonic acid monohydrate, 60 and 1000 ml. of benzene. The reaction mixture was heated to refluxing temperature under a nitrogen atmosphere for one hour in an apparatus equipped with a Dean-Stark water trap. The reaction mixture was then cooled and the solvent and other volatile 65 materials removed by evaporation in vacuo. The residue, comprising the pyrrolidine enamine of 4 -benzoyloxycyclohexanone formed in the above reaction was dissolved without further purification in 1000 ml. of dioxane. 42.6 g. of acrylamide were 70 added. This new reaction mixture was heated under a nitrogen atmosphere at reflux temperature for twenty-one hours. Thin-layer chromatography of the reaction mixture indicated one major spot. The reaction mixture was cooled and the volatile constituents 75 removed by evaporation in vacuo. A chloroform solution of the residue comprising 6 - benzoyloxy -3,4,5,6,7,8 - hexahydro -1H - quinolin - 2 - one and the isomeric product 6 - benzoyloxy - 3,4,4a,5,6,7 -hexahydro -1H - quinolin - 2 - one was chromatog-80 raphed over350 g. of florisil using chloroform containing increasing quantities of ethanol (0 to 2 percent) as the eluant. Fractions found to contain 6 -benzoyloxy-3,4,5,6,7,8- hexahydro - 1H - quinolin-2 - one and its isomer by thin-layer chromatography 85 were combined and the solvent removed therefrom in vacuo. The resulting residue was crystallized by triturating with hexaneto yield a crystalline mixture of 6 - benzoyloxy - 3,4,5,6,7,8 - hexahydro -1H -quinolin - 2 - one and the corresponding 3,4,4a,5,6,7 -90 hexahydro derivative. The mixture melted in the range 130-150°C. after recrystallization from an ether-hexane solvent mixture.
Analysis: Calculated: C, 70.83; H, 6.32; N, 5.16;
Found: C, 71.05; H, 6.19; N, 5.33.
95 NMR of the product isolated above indicated that the mixture contained about 60 percent of 6 - benzoyloxy - 3,4,5,6,7,8 - hexahydro -1H - quinolin - 2 -one and 40% of the 3,4,4a,5,6,7 - hexahydro isomer.
46.5 g. of the above isomer mixture were dissolr 100 ved in 400 ml. oftetrahydrofuran (THF). 80 ml. of methyl iodide were added and the resulting mixture cooled in an ice-water bath. 9.6 g. of sodium hydride (as a 50 percent suspension in mineral oil) were added in portions. After all of the sodium hydride 105 suspension had been added, the cooling bath was removed and the reaction mixture stirred at ambient temperature under a nitrogen atmospherforabout4 hours. The reaction mixture was then diluted with water and the aqueous mixture thoroughly extracted 110 with chlorofrom. The chloroform extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and dried. The chloroform was removed by evaporation to dryness in vacuo leaving as a residue an orange oil weighing 115 47.3 g. Recrystallization from an ether-hexane solvent mixture yielded crystals of 1 - methyl - 6 - benzoyloxy - 3,4,5,6,7,8 - hexahydro - 2(1 H) - quinolinone and the corresponding 3,4,4a,5,6,7 - hexahydro isomer.
120 Analysis: Calculated: C, 71.56; H, 6.71; N,4.91;
Found: C, 71.33; H, 6.90; N, 4.67.
Following the above procedure, 59 g. of a mixture of 6 - benzoyloxy - 3,4,5,6,7,8 - hexahydro - 2(1 H) -quinolinone and 6 - benzoyloxy - 3,4,4a,5,6,7 - hex-125 ahydro - 2(1 H) - quinolinone were reacted with n-propyl iodide in the presence of sodium hydride to yield 1 - n - propyl - 6 - benzoyloxy - 3,4,5,6,7,8 -hexahydro - 2(1 H) - quinolinone and the corresponding 3,4,4a,5,6,7 - hexahydro isomer. The compounds 130 were purified by chromatography overflorisil using
6
GB 2 040 917 A
6
an ether-chloroform solvent mixture as the eluant. Also following the above procedure, a mixture of the 1 - benzyl - 6 - benzoyloxyhexahydro - 2(1 H) -quinolinones was prepared by substituting benzyl 5 bromide for methyl iodide.
A solution of 47.3 g. of a mixture of 1 - methyl-6-benzoyloxy - 3,4,5,6,7.8 - hexahydro - 2(1 H) -quinolinone and the corresponding 3,4,4a,5,6,7 -hexahydro isomer as obtained above were dissolved 10 in 800 ml. of THF and the solution cooled to about 0°C. 20 g. of lithium aluminum hydride were added thereto in portions and the resulting mixture refluxed for four hours under a nitrogen atmosphere. The reaction mixture was cooled and excess 15 lithium aluminum hydride destroyed by the addition of ethyl acetate. 10% sodium hydroxide was then added and the mixture diluted with water to decompose any organometallics present. The aqueous mixture was extracted several times with a 20 chloroform-isopropanol solvent mixture. The organic extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent yielded as a residue a mixture of the enamines -1 -25 methyl - 6 - hydroxy -1,2,3,4,5,6,7,8 - octahydro-quinoline and 1 - methyl - 6- hydroxy-1,2,3,4,48,5,6,7 - octahydroquinoline-formed in the above reaction. (The lithium aluminum hydride reduction served to remove the benzoyl group at C-6 30 as a benzyl alcohol moiety, leaving a free hydroxy in that position of the ring). The above residue, without further purification, was dissolved in about 300 ml. of ether and the ethereal solution saturated with gaseous hydrogen chloride, thus forming the hyd-35 rochloride salt of the enamine mixture. The ether was removed by decantation and the residue dissolved in a mixture of 200 ml. of THF and 50 ml. of methanol. This solution was cooled in an ice water bath. 12 g. of sodium cyanoborohydride were added 40 with cooling and stirring. After all of the cyanoborohydride had been added, the reaction mixture was stirred for another 60 minutes and then poured over a mixture of ice and 1N aqueous hydrochloric acid. The acidic aqueous solution was 45 extracted with chloroform and the chloroform extract discarded. The solution was then made basic with 14N aqueous ammonium hydroxide. Trans - dl -1 - methyl - 6 - hydroxydecahydroquinoline formed in the above reaction, being insoluble in the alkaline 50 medium, separated and was extracted several times with a chloroform-isopropanol solvent mixture. The combined extracts were washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent yielded 15 g. of trans - dl -1 -55 methyl - 6 - hydroxydecahydroquinoline.
Following the above sequence of reactions, a mixture of 1 - n - propyl - 6 - benzoyloxy - 3,4,5,6,7,8 -hexahydro - 2(1 H) - quinolinone and the corresponding 3,4,4a,5,6,7, - hexahydro isomer were first 60 reduced with lithium aluminum hydride to yield a mixture of A4a and A81 - n - propyl - 6 - hydroxyocta-hydroquinolines which was converted by treatment with ethereal hydrogen chloride to the enamine hydrochloride. Reduction of this intermediate enamine 65 hydrochloride with sodium cyanoborohydride yielded trans - dl -1 - n - propyl - 6 -hydroxydecahydroquinoline (56 g. of starting material yielded 30 g of product). Also following the above procedure, 1 - benzyl - 6 - benzoyloxy - 3,4,5,6,7,8 -70 hexahydro - 2(1 H) - quinolinone in admixture with 1 -benzyl - 6 - benzoyloxy - 3,4,4a,5,6,7 - hexahydro -2(1 H) - quinolinone was reduced with lithium aluminum hydride to yield the corresponding 1 - " benzyl - 6 - hydroxy -1,2,3,4,5,6,7,8 - octahydro-75 quinoline and 1 - benzyl - 6 - hydroxy -
1,2,3,4,4a,5,6,7 - octahydroquinoline as a mixture, treatment of which with ethereal hydrogen hydrochloride yielded the enamine salt. Reduction of the enamine salt with sodium cyanoborohydride gave 1 80 - benzyl - 6 - hydroxydecahydroquinoline (65 g. of starting mixture yielded 49.6 g. of final product).
Fifteen grams of trans - dl -1 - methyl - 6 -hydroxydecahydroquinoline were dissolved in 250 ml. of 6N aqueous sulfuric acid. The solution was 85 cooled in an ice-water bath. A solution of 9 g. of chromium trioxide in 60 ml. of 6N aqueous sulfuric acid were added thereto with stirring in dropwise fashion over a 10-minute period. The cooling bath was removed and the reaction mixture stirred for an 90 additional 60 minutes at ambienttemperature. The excess oxidizing agent was decomposed by adding isopropanol to the reaction mixture. The reaction mixture was next poured over ice and the acidic aqueous solution made basic with 14N aqueous 95 ammonium hydroxide, trans - dl -1 - Methyl - 6 -oxodecahydroquinoline thus formed, being insoluble in the alkaline layer, separated and was extracted several times with a mixture of chloroform and isopropanol. The extracts were combined and the com-100 bined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent in vacuo yielded trans - dl -1 - methyl - 6 -oxodecahydroquinoline boiling in the range 105-116°C. at 6 torr; yield = 7.7 g. (45%). 105 Following the above procedure, 29.5 g. of trans - dl -1 - n - propyl - 6 - hydroxydecahydroquinoline were dissolved in 300 ml. of glacial acetic acid to which was added 8 ml. of 18N aqueous sulfuric acid. 55 mi. of a solution of 26.7 g. of chromium trioxide in 23 ml. 110 of 18M sulfuric acid were added in drop-wise fashion. trans - dl -1 - n - Propyl - 6 - oxodecahydroquinoline formed in the above reaction was isolated by the above procedure; yield = 21.4 g. Still following the above procedure, 49.6 g. of trans - dl -1 -115 benzyl - 6 - hydroxy - decahydroquinoline were oxidized with chromium trioxide in sulfuric acid to yield trans - dl -1 - benzyl - 6 - oxodecahydroquinoline; yield = 21.1 g. of a dark oil.
A reaction mixture was prepared from 7.7 g. of ' 120 trans-dl-1 - methyl-6-oxodecahydroquinoline,36 g. of the dimethyl acetal of dimethylformamide and 250 ml. of benzene. Benzene was removed by distillation at atmospheric pressure under nitrogen until about 1/2 the original volume remained (1.25 hours). 125 Sufficient benzene was then added to make up the volume to the original volume and the process was repeated (four times). All of the benzene was finally removed by evaporation in vacuo and the resulting residue dissolved in 100 g. of dimethylformamide 130 dimethylacetal. This solution was heated to refluxing
7
GB 2 040 917 A
7
temperature under nitrogen for 20 hours. The reaction mixture was then evaporated in vacuo and the chloroform solution of the residue chromatographed over 150 g. of florisil using as the eluant, methylene 5 dichloride containing increasing amounts (1-5%) of methanol. Fractions containing similar compounds as shown by TLC were combined. The third substance to come off the column was a yellow solid (wt = 3 g.) The solid was heated with 100 ml. of ether 10 and the resulting solution filtered. Concentration of the filtrate to about 50 ml. yielded 590 mg. of trans -dl -1 - methyl - 6 - oxo - 7 - dimethylamino-methylenedecahydroquinoline melting at 107-109°C.
Analysis: Calculated : C, 70.23; H, 9.97; N 12.60; 15 Found: C, 70.17; H, 9.74; N, 12.87.
The above reaction was repeated except that trans - dl -1 - n - propyl - 6 - oxodecahydroquinoline was used as a starting material and the product was chromatographed over florisil using chloroform con-20 taining increasing quantities of methanol (1-5%) as the eluant. trans - dl -1 - n - Propyl - 6- oxo - 7 -dimethylaminomethylenedecahydroquinoline was obtained.
Following the above procedure, trans - dl -1 - ben-25 zyl - 6 - oxodecahydroquinoline was reacted with dimethylformamide dimethylacetal to yield trans - dl -1 - benzyl - 6 - oxo - 7 - dimethylamino-methylenedecahydroquinoline melting at 109-111°C. after recrystallization from an ether-hexane solvent 30 mixture.
Analysis: Calculated: C, 76.47; H,8.78; N, 9.29;
Found: C, 76.25; H, 8.66; N, 9.36.
The potassium salt of glycine was prepared by reacting 975 mg. of glycine with 730 mg. of potas-35 sium hydroxide in 100 ml. of anhydrous ethanol. 2.8 g. of trans - dl -1 - methyl - 6 - oxo-7-dimethylaminomethylenedecahydroquinoline were added and the resulting mixture heated at reflux temperature under nitrogen for about 3 hours. The 40 reaction mixture was cooled, the volatile constituents removed in vacuo and the residue diluted with ether. The resulting mixture was filtered and the adduct weighed 3.5 g. The glycine adductwas then cyclized, decarboxylated and acetylated by heating 45 with 100 ml. of acetic anhydride at reflux temperature under nitrogen for about 45 minutes. The acety-lation mixture was cooled and the volatile constituents removed by evaporation to dryness. The residue, comprising trans - dl - 2 - acetyl - 5 - methyl -50 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline was suspended in methylene dichloride and the suspension filtered to yield 1.7 g. of solid. The methylene dichloride filtrate was chromatographed over 150 g. of florisil using methylene dich-55 loride containing increasing (0-5%) amounts of methanol as the eluant. Fractions shown by TLC to contain the same substance were combined, and the combined fractions washed with sodium bicarbonate and saturated aqueous sodium chloride and 60 then dried. Evaporation of the solvent in vacuo yielded a residue which was rechromatographed over 30 g. of florisil using chloroform containing 5% methanol as the eluant. Fractions shown by TLC to contain the same substance were combined to yield 65 1.72 g. of a viscous orange oil comprising purified trans - dl - 2 - acetyl - 5 - methyl - 4,4a,5,6,7,8,8a,9 -octahydro - 2H - pyrrolo [3,4-g] quinoline. The orange oil was dissolved in ether and a solution of 870 mg. of maleic acid in ether added thereto. The 70 maleate salt thus formed melted at201-203°G. after recrystallization from methanol ether solvent mixture (1:2).
Analysis: Calculated: C, 62.05; H, 6.94; N, 8.04;
Found: C, 61.81; H, 6.82; N, 7.97.
75 Following the above procedure, trans - dl - 2 -acetyl - 5 - n - propyl - 4,4a,5,6,7,8,9 - octahydro - 2H -pyrrolo [3,4-g] quinoline was prepared from trans-dl - 2 - n - propyl - 6 - oxo - 7 - dimethylamino-methylenedecahydroquinoline by reaction with the 80 potassium salt of glycine followed by acetic anhydride. The compound was purified by chromatography.
Following the above procedure, trans - dl -1 - benzyl - 6 - oxo - 7 - dimethylaminomethylene-85 decahydroquinolinewas reacted with the potassium salt of glycine and acetic anhydride to yield trans - dl
- 2 - acetyl - 5 - benzyl - 4,4a(5,6,7,8,8a,9 - octahydro -2H - pyrrolo [3,4-g] quinoline. This latter derivative was purified by chromatography overflorisil and
90 then converted to the maleate salt. Trans - dl - 2 -acetyl - 5 - benzyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H -pyrrolo [3,4-g] quinoline maleate melted at 162-164°C. After recrystallization from a methanol-ether solvent mixture.
95 Anaiysis: calc.: C, 67.91; H, 6.65; N, 6.60;
Found: C, 67.76; H, 6.40; N, 6.58.
Example B
Preparation of trans - dl - 2 - Acetyl - 5 - n - Propyl -4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] 100 quinoline.
A solution was prepared from 2.5 g. of trans - dl - 2
- acetyl - 5 - benzyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H
- pyrrolo [3,4-g] quinoline and 200 ml. of methylene dichloride. 4 g. of cyanogenbromide were added and
105 the resulting mixture was stirred at ambient temperature under a nitrogen atmosphere for about 16 hours. Volatile constituents were removed by evaporation in vacuo. A chloroform solution of the residue containing trans - dl -1 - acetyl - 5 - cyano -110 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline formed in the above reaction was chromatographed over 200 g. of fiorisil using chloroform as the eluant. Fractions shown to contain the desired compound were combined and the sol-115 vent removed therefrom. Recrystallization of the residue from ether yielded crystalline trans-dl -2-acetyl - 5 - cyano - 4,4a, 5,6,7,8,8a,9 - octahydro - 2H -pyrrolo [3,4-g] quinoline melting at 135-7°C. (total yield = 630 mg.)
120 A mixture of 0.6 g. of trans - dl - 2- acetyl - 5-cyano - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline, 50 ml. of glacial acetic acid, 10 ml. of water and 3 g. zinc dust was heated at refluxing temperature under a nitrogen atmosphere for about 125 7 hours. The reaction mixture was then filtered and the filtrate poured over ice. The aqueous filtrate was then made basic with 14N aqueous ammonium hydroxide. The aqueous alkaline layer was extracted several times with a mixture of chloroform and isop-130 ropanol. The organic extracts were combined and
8
GB 2 040 917 A
8
the combined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the solvent in vacuo yielded a residue which was shown to be one-spot material by TLC. The residue 5 was dissolved in 50 ml. of dimethylformamide to which was added 0.8 g. potassium carbonate and 0.4 ml. of n-propyl iodide. This reaction mixture was stirred at ambient temperature under a nitrogen atmosphere for about 16 hours. The reaction mixture 10 was then diluted with water and the diluted mixture extracted with ethyl acetate. The ethyl acetate extract was washed with water and saturated aqueous sodium chloride and then dried. Evaporation of the solvent in vacuo yielded a residue shown to con-15 tain one major spot by TLC of the product, trans - 2 -acetyl - 5 - n - propyl - 4,4a,5,6,7,8,8a,9 - octahydro -2H - pyrrolo [3,4-g] quinoline.
Example C
Preparation of trans - dl - 2 - Acetyl - 4,4a,5,6,7,8,8a,9 20 - octahydro - 2H - pyrrolo [3,4-g] quinoline.
3.5 Grams of trans - dl - 2 - acetyl - 5 - benzyl -4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline were dissolved in 196 ml. of ethanol to which solution was added 0.5 g. of a 5% palladium -25 on - carbon catalyst. The mixture was hydrogenated in an Adams machine at room temperature at an initial hydrogen pressure of 4.13 x 106 dynes/cm.2. After 2 hours, 100% of the theoretical amount of hydrogen had been absorbed. The hydrogenation mix-30 ture was removed from the machine and the catalyst separated by filtration. TLC indicated that there were two major spots, one being starting material. The filtrate was concentrated in vacuo to yield crystalline material. Concentration of the filtrate yielded a 35 further batch of crystalline material. These two batches were combined, dissolved in water and the aqueous solution made basic with 14N aqueous ammonium hydroxide. The alkaline layer was extracted several times with a mixture of chloroform 40 and isopropanol. The organic extracts were combined and the combined extracts were washed with saturated aqueous sodium chloride and dried. Evaporation of the solvent yielded a residue comprising trans - dl - 2 - acetyl - 4,4a,5,6,7,8,8a,9 - octahydro -45 2H - pyrrolo [3,4-g] quinoline formed in the above hydrogenation. The residue was washed with hex-ane. It melted at Sg^l^C. The maleate salt was prepared by dissolving the residue in ether and adding an excess of maleic acid in ether. The maleate salt 50 was recrystallized from a mixture of methanol and ether and melted at 150-1 °C.
Example D Preparation of trans - dl - 4,4a,5,6,7,8,8a,9 -Octahydro - 2H - pyrrolo [3,4-g] quinoline. 55 Three-tenths grams of trans - dl - 2 - acetyl -4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline were dissolved in 15 ml. methanol to which was added 2 ml. of 2N aqueous sodium hydroxide. The hydrolysis mixture was stirred at 60 ambient temperature under nitrogen for 3/4 hours. The reaction mixture was then diluted with water and the alkaline layer extracted with a mixture of chloroform and isopropanol. The organic extract was separated, washed with saturated aqueous 65 sodium chloride and then dried. Evaporation of the solvent yielded a residue showing a single spot by TLC. The residue was dissolved in ether and an excess of an ethereal solution of maleic acid added thereto. The resulting gummy precipitate was sepa-. rated, dissolved in methanol, and the methanol solution diluted with etherto yield crystalline material, trans - dl - 4,4a,5,6,7,8,8a,9 - Octahydro - 2H - pyrrolo [3,4-g] quinoline maleate thus prepared melted at 190°C. with decomposition.
Example E
Preparation of 1 - n - Propyl - 6 - benzoyloxy -3,4,5,6,7,8 - hexahydro - 2(1 H) - quinolinone and 1 - n
- Propyl - 6 - benzoyloxy - 3,4,4a,5,6,7 - hexahydro -2(1 H) - quinolinone
A reaction mixture was prepared containing 4.4 g. of 4- benzoyloxycyclohexanone [prepared by the procedure of E. R. H. Jones and F. Sondheimer,^/. Chem. Soc., 615 (1949)], 2.5 ml. of n-propylamine and 100 ml. toluene. The mixture was heated to reflux temperature in a nitrogen atmosphere using a Dean Stark water trap for about 2 hours. The reaction mixture was then heated to refluxing temperature for an additional 2 hours in the presence of a molecular sieve to remove water. The reaction mixture was then cooled and the solvent removed by evaporation in vacuo. 4 ml. of methyl acrylate and 100 ml. of dioxane were added to the residue which was then refluxed overnight under a nitrogen atmosphere. The reaction mixture was again cooled and the volatile constituents removed by evaporation in vacuo. Chromatography of an ethereal solution of the resulting residue over 200 g. of florisil using ether as an eluant yielded a mixture of 1 - n - propyl - 6 -benzoyloxy - 3,4,5,6,7,8 - hexahydro-2(1 H) -quinolinone and 1 - n - propyl - 6 - benzoyloxy -3,4,4a,5,6,7 - hexahydro - 2(11-1) - quinolinone: yield = 2.15 g.
Example F
Preparation of trans - dl - 2 - Acetyl - 5 - n - propyl - 7 -ethoxycarbonyl - 4,4a,5,6,7,8,8a,9 - octahydropyrrolo -[3,4-g] quinoline
A mixture of 10 ml. of n-propyl amine and 400 ml. of toluene were cooled in an ice-water bath. A solution of 16.5 g. of ethyl a- (bromomethyl) - acrylate in 50 ml. of toluene was added thereto in dropwise fashion. The resulting mixture was stirred with cooling for about 25 minutes. Next, a solution of 11 g. of 4- benzoyloxycyclohexanone in 75 ml. of toluene was added in dropwise fashion. This new mixture was heated under a nitrogen atmosphere to refluxing temperature for about 23 hours. The reflux condenser was equipped with a Soxhlet extractor containing a 5A sieve to remove water. Next the reaction mixture was cooled and the cooled mixture filtered". Evaporation of the filtrate yielded a residue comprising a mixture of 1 - n - propyl - 3- ethoxycarbonyl-6-benzoyloxy-1,2,3,4,5,6,7,8 - octahydroquinoline " and 1 - n - propyl -3 - ethoxycarbonyl -6- benzoyloxy
- 1,2,3,4,4a,5,6,7 - octahydroquinoline. The residue was dissolved in an ether-chloroform solvent mixture and the resulting solution saturated with gaseous hydrogen chloride while maintaining the temperature in the range 0-5°C. The solvent was decanted from the crystalline hydrochloride salts thus formed. The salts were dissolved in 100 ml. of methanol. 300
70
75
80
85
90
95
100
105
110
115
120
125
130
9
GB 2 040 917 A
9
ml. of THF were added and the resulting solution cooled in an ice-water bath. 15 g. of sodium cyanoborohydride were added in portions to the stirred and cooled reaction mixture. Afterthe addition 5 had been completed, the reaction mixture was stirred for another 1.25 hours after which time it was diluted with aqueous sodium bicarbonate. The aqueous alkaline mixture was extracted several times with ethyl acetate. The ethyl acetate extracts 10 were combined and the combined extracts washed with saturated aqueous sodium chloride solution and then dried. Evaporation of the solvent yielded trans - dl -1 - n - propyl - 3 - ethoxycarbonyl - 6 -benzoyloxydecahydroquinoline. The compound was 15 dissolved in a mixture of 400 ml. of methanol and 100 ml. of 2N aqueous sodium hydroxide. This mixture was stirred at ambient temperature undera nitrogen atmosphere for 64 hours after which time the volatile constituents were removed by evaporation 20 in vacuo. The resulting residue was suspended in 800 ml. of ethanol and 15 ml. of 12N aqueous hydrochloric acid. The esterification mixture was heated to refluxing temperature and about 300 ml. of solvent removed by distillation. 300 ml. of additional 25 ethanol were added and the reaction mixture heated to refluxing temperature for 26 hours in an apparatus equipped with a Soxhlettrap containing a 3A sieve. The reaction mixture was cooled, diluted with aqueous sodium bicarbonate and the alkaline 30 mixture extracted several times with chloroform. The chloroform extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloroform yielded 10.3 g. of a residue which was 35 purified by chromatography over 150 g. of florisil using chloroform containing increasing (2-10%) of methanol as the eluant. Trans - dl -1 - n - propyl - 3 -ethoxycarbonyl - 6 - hydroxydecahydroquinoline formed in the above reaction was obtained from the 40 eluate fractions as a purified product.
A solution was prepared from 8.8 g. of trans - dl -1 - n - propyl - 3 - ethoxycarbonyl - 6 -hydroxydecahydroquinoline and 400 ml. of methylene dichloride. 41 g. of sodium acetate were 45 added. Next, 10.8 g. of pyridine hydroch-
loride:chromium trioxide were added and the resulting mixture stirred for about 22 hours. The reaction mixture was filtered and the filtrate concentrated in vacuo. The resulting concentrate was dissolved in 50 chloroform and the chloroform solution chromatographed over 150 g. of florisil using chloroform containing increasing amounts (1-2%) of methanol as the eluant. Fractions shown by thin-layer chromatography to contain trans -dl-1 -n-propyl -55 3 - ethoxycarbonyl - 6 - oxodecahydroquinoline formed in the above reaction were combined and the ' solvent removed from the combined extracts to yield 3.48 g. of the 6-oxo compound as a residue. The 6-oxo compound was dissolved in 100 ml. of toluene 60 containing an added 25 ml. of the dimethylacetal of dimethylformamide. The resulting mixture was heated to refluxing temperature under a nitrogen atmosphere for 44 hours and was then allowed to remain at room temperature for an additional 4 days. 65 Volatile constituents were removed by evaporation in vacuo and the residue, comprising trans - dl -1 - n - propyl - 3 - ethoxycarbonyl - 6 - oxo - 7 -(dimethylaminomethylene) decahydroquinoline formed in the above reaction, was purified by 70 chromatographing a chloroform solution of the compound overflorisil using chloroform containing increasing amounts (2-5%) of methanol as the eluant. Fractions shown by TLC to contain the desired 7 - dimethylaminomethylene compound 75 were combined and the solvent evaporated therefrom in vacuo.
The potassium salt of glycine was prepared by reacting 280 mg. of potassium hydroxide with 370 mg. of glycine in 50 ml. of anhydrous ethanol. 1.3 g. 80 of trans - dl -1 - n - propyl - 3 - ethoxycarbonyl - 6-oxo - 7 - (dimethylaminomethylene) decahydroquinoline were added and the resulting mixture heated under a nitrogen atmosphere to reflux temperature for about 3 hours. The reaction mixture was 85 cooled and the volatile constituents removed by evaporation in vacuo. 50 ml. of acetic anhydride were added to this residue and the resulting mixture heated to reflux temperature undera nitrogen atmosphere for about 45 minutes thus cyclizing, 90 decarboxylating and acetylating all in one step. Again, the reaction mixture was cooled and the volatile constituents removed by evaporation. In this instance, the residue was next diluted with aqueous sodium bicarbonate and the resulting alkaline aque-95 ous layer extracted with chloroform. The chloroform extract was separated and the separated extract washed with saturated aqueous sodium bicarbonate and then dried. Evaporation of the chloroform yielded a residue which was chromatographed over 100 35 g. of florisil using chloroform containing increasing amounts (0-1%) of methanol as the eluant. Fractions shown by TLC to contain the desired trans - dl -2 - acetyl - 5 - n - propyl - 7 - ethoxycarbonyl -4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline 105 formed in the above reaction were combined. The solvent was removed from the combined fractions by evaporation and the resulting residue was dissolved in ether. This ether solution was treated with an excess of maleic acid, also in ether. The resulting 110 precipitate comprising the maleate salt of trans - dl -2 - acetyl - 5 - n - propyl - 7 - ethoxycarbonyl -4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline melted at 179-180°C. after crystallization from a methanol-ether solvent mixture; yield = 280 mg. 115 Analysis Calculated: C, 61.59; H,7.19; N,6.25;
Found: C,61.32; H, 6.97; N, 6.53.
690 mg. of trans - dl - 2 - acetyl - 5 - n - propyl - 7 -ethoxycarbonyl - 4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline maleate were dissolved in ethanol 120 and this solution added to a solution containing an excess of sodium ethylate in ethanol. The reaction mixture was stirred for 1/2 hour after which time it was diluted with water and the aqueous mixture extracted with chloroform. The chloroform extract 125 was separated, washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloroform yielded trans - dl - 5 - n - propyl - 7 -ethoxycarbonyl - 4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline formed in the above reaction. The 130 free base melted at 163-4°C. after recrystallization
10
GB 2 040 917 A
10
from ethanol.
Analysis calculated: C, 70.31; H, 9.02; N, 9.65;
Found: C, 70.22; H, 8.91; N, 9.94.
About 1/2 gram of trans - dl - 5 - n - propyl - 7 -5 ethoxycarbonyl - 4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline were dissolved in 75 ml. of tet-rahydrofuran. 1 g. of lithium aluminumhydride was added thereto in small portions. After all of the lithium aluminumhydride had been added, the reac-10 tion mixture was stirred for another 2.25 hours after which time the excess lithium aluminumhydride was decomposed by the addition of ethyl acetate and any organometallic salts present decomposed by the addition of 10% aqueous sodium hydroxide. The 15 resulting mixture was diluted with water and the aqueous layer extracted several times with chloroform. The chloroform extracts were separated and combined and the combined extracts washed with saturated aqueous sodium chloride and then 20 dried. Evaporation of the solvent yielded as a residue, trans - dl - 5 - n - propyl - 7 - hydroxymethyl -4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline, which melted at 178-180°C. after recrystallization from a ethyl acetate/ether solvent mixture. 25 Analysis calculated: C, 72.54; H, 9.74; N, 11.28
Found: C, 72.30; H, 9.73; N, 11.05.
About 0.4 g. of trans - dl - 5 - n - propyl - 7 - hydroxymethyl - 4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline were dissolved in 25 ml. of pyridine. 0.5 30 ml. of methanesulfonyl chloride were added and the resulting mixture stirred for 0.75 hours at room temperature. The reaction mixture was diluted with water and sufficient 14N aqueous ammonium hydroxide added to make the reaction mixture basic. 35 The aqueous mixture was extracted several times with ethyl acetate. The ethyl acetate extracts were combined and the combined extracts washed first with water and then with saturated aqueous ammonium chloride and were then dried. The 40 residue obtained by evaporation of the solvent was chromatographed over 30 g. of florisil and the chromatogram develop with chloroform containing increasing quantities (2-4%) of methanol as the eluant. Fractions shown by thin-layer chromatogra-45 phy to contain the desired methanesulfonyl ester were combined and the solvent removed therefrom in vacuo. The resulting residue, trans - dl - 5 - n -propyl - 7 - mesyloxymethyl - 4,4a5,6,7,8,8a,9 -octahydropyrrolo [3,4-g] quinoline was crystallized 50 from ethanol; m.p. = 150°C. with decomposition.
FINAL PRODUCTS Example 1
Preparation of trans - dl - 5 - Methyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline from the 55 Corresponding 2-Acetyl Compound.
One and two-tenths grams of trans - dl - 2 - acetyl -5 - methyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline maleate were suspended in 100 ml. of methanol and 10 ml. of 2N aqueous 60 sodium hydroxide were added. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for about 35 minutes and was then diluted with dilute aqueous sodium hydroxide. The resulting alkaline solution was extracted several 65 times with chloroform. The chloroform extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and dried. Evaporation of the chloroform yielded 400 ml. of crystalline material melting at 190-6°C. with decomposition. A chloroform solution of the material was then chromatographed over 30 g. of florisil using chloroform containing increasing amounts (2-5%) of methanol as the eluant. The second major component to be eluted from the column consisted of trans
- dl - 5 - methyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H -pyrrolo [3,4-g] quinoline. Fractions containing this compound were combined and the solvent removed from the combined fractions by evaporation. Recrystallization of the residue from ether yielded trans-dl
- 5 - methyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline melting at200-222°C. with decomposition (80 mg.).
Analysis: caic.: C,75.74 H, 9.53; N, 14.72;
Found: C, 75.88 H, 9.28; N, 14.55.
Following the above procedure, trans - dl - 2 -acetyl - 5 - n - propyl -4,4a,5,6,7,8,8a,9 - octahydro -2H - pyrrolo [3,4-g] quinoline (4.8 g) was hydrolyzed with dilute aqueous sodium hydroxide, trans - dl - 5 -n - Propyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline thus prepared was purified by chromotography overflorisil using chloroform containing increasing amounts (2-10%) methanol as the eluant. Fractions shown to contain the desired product by TLC were combined and the solvent evaporated therefrom. Recrystallization of the residue from a methanol-ether solvent mixture yielded 245 mg. crystalline trans - dl - 5 - n - propyl -4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline melting at 169-171°C. with decomposition; nmr peaks at 52,384 and 510 cps. (in CDCI3).
Analysis: calc.: C, 64.65; H, 7.84; N, 8.38;
Found: C, 64.40; H,7.62; N,8.12.
Example 2 Prepa ration of trans - dl - 5 - n - Propyl -4,4a,5,6,7,8,8a,9 -octahydro - 2H - pyrrolo [3,4-g] quinoline.
The product trans - dl - 2 - acetyl - 5 - n - propyl -4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo [3,4-g] quinoline (from Example B) was dissolved in 20 ml. of methanol to which was added 3 ml. of 2N aqueous sodium hydroxide. This reaction mixture was stirred at ambient temperature undera nitrogen atmosphere for 65 min. The reaction mixture was diluted with water and the diluted mixture extracted several times with chloroform. The chloroform extracts were combined and the combined extracts washed with saturated aqueous sodium chloride and then dried. Evaporation of the chloroform yielded a residue -which was shown to contain one major spot by TLC\ An ether solution of the residue, comprising trans -dl - 5 - n - propyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H -pyrrolo [3,4-g] quinoline formed in the above reac-' tion, was treated with an excess of maleic acid in ether solution, thus forming the maleate salt of the base. The maleate salt was separated by filtration and recrystallized from an ether-methanol solvent mixture, trans - dl - 5 - n - Propyl - 4,4a,5,6,7,8,8a,9 -octahydro - 2H - pyrrolo [3,4-g] quinoline maleate thus prepared melted 168-170°C, with decomposition; yield = 215 mg.
70
75
80
85
90
95
100
105
110
115
120
125
130
11
GB 2 040 917 A
11
Example 3
The mesylate ester (prepared in Example F) can be reacted with the sodium salt of methylmercaptan to yield trans - dl - 5 - n - propyl - 7 - methylmercapto-5 methyl - 4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline.
As evidence of the utility of the compounds of formula I, it has been found that they affect turning behaviour in rats in a test procedure designed to 10 uncover compounds useful forthe treatment of Parkinsonism utilizing 6 - hydroxydopamine - lesioned rats. In this test, nigroneostriatal - lesioned rats are employed, as prepared by the procedure of Ungers-tedt and Arbuthnott, fir/an Res, 24,485 (1970). A 15 compound having dopamine agonist activity causes the rats to turn in circles contralateral to the side of the lesion. After a latency period, which varies from compound to compound, the number of turns is counted over a 15-minutes period.
20 Results obtained from testing representative compounds of formula I in the rat turning test are set forth in Table 1 below. The compounds were dissolved in water and the aqueous solution injected into the rat by the intraperitoneal route at a dose level of
25 1 mg/kg. In the table, column 1 gives the name of the compound, column 2, percent of test animals exhibiting turning behaviour, and column 3, average number of turns observed in first 15 minutes after end of latency period.
Table 1
Name of Compound trans-dl-5-n-Propyl-4,4a,5,6,-7,8,8a,9-octahydro-2H-pyrrolo[3,4-g]quinoline maleate trans-dl-5-Methyl-4,4a,5,6,7,8,-8a,9-octahydre-2H-pyrrolo[3,4-g] quinoline maleate
30 The compounds of formula I are also useful as prolactin inhibitors and as such they can be employed in the treatment of inappropriate lactation 50 such as postpartum lactation and galactorrhea. As evidence of their utility in the treatment of diseases 35 such as those in which it is desirable to reduce the prolectin level, the compounds of formula I have been shown to inhibit prolactin according to the fol- 55 lowing procedure.
Adult male rats of the Sprague-Dawley strain 40 weighing about 200 g. were housed in an air-
controlled room with controlled lighting (lights on 6 a.m. - 8 p.m.) and fed lab chow and water ad libitum. 60 Each rat received an intraperitoneal injection of 2.0 mg. of reserpine in aqueous suspension 18 hours 45 before administration of the test drug. The purpose of the reserpine was to keep prolactin levels uniformly elevated. The compounds under test were
% of Rats Exhibiting Turning Behavior
100
Average Number of Turns/rat
169
33
20
dissolved in 10 percent ethanol, and were injected intraperitoneally at doses of 0.5 and 5 mg/kg. Each compound was administered at each dose level to a group of 10 rats, and a control group of 10 intact males received an equivalent amount of 10 percent ethanol. One hour after treatment, all rats were killed by decapitation, and 150 /xl aliquots of serum were assayed for prolactin.
The difference between the prolactin level of the treated rats and prolactin level of the control rats, divided by the prolactin level of the control rats gives the percent inhibition of prolactin secretion attributable to the compounds of formula I. These inhibition percentages are given in Table 2 below. In the table, column 1 gives the name of the compound; and columns 2 and 3, the percent prolactin inhibition at the 0.5 and 5 mg/kg dose levels.
Table 2
Name of Compound trans-dl-5-n-Propyl-4,4a,5, 6,7,8,8a,9-octahydro-2H-pyrrolo [3,4-g]quinoline maleate
Percent Prolactin Inhibition at Given Dose 0.5 mg I kg 5mglkg trans-dl-5-Methyl-4,4a,5,6,
7,8,8a,9-octahydro-2H-pyrrolo
[3,4-g]quinoline maleate 23 90
65 In using the compounds of formula I to inhibit prolactin secretion or to treat Parkinson's syndrome or for other pharmacologic action, a compound according to formula I above in which R2 is C1-C3 alkyl or allyl and R1 is H or CVC3 alkyl, or a salt thereof with a 70 pharmaceutically - acceptable acid, is administered
12
GB 2 040 917 A
12
to a subject suffering from Parkinsonism or in need to having his prolactin level reduced in an effective amount to treat Parkinsonism orto reduce prolactin. Oral administration is preferred. If parenteral 5 administration is used, the injection is preferably by the subcutaneous route, using an appropriate pharmaceutical formulation. Other modes of parenteral administration such as intraperitoneal, intramuscular, or intravenous routes are equally effective. In 10 particular, with intravenous or intramuscular administration, a water soluble pharmaceutical^ -acceptable salt is employed. For oral administration, the compound either as the free base or in the form of a salt thereof can also be mixed with standard 15 pharmaceutical excipients and loaded into empty telescoping gelatin capsules or pressed into tablets. For oral administration, the compound either as the free base or in the form of a salt thereof, can also be mixed with standard pharmaceutical excipients and 20 loaded into empty telescoping gelatin capsules or pressed into tablets. The oral dosage range is from about 0.01 to 10 mg. to 10 mg./kg. of mammalian weight and the parenteral dose range from about 0.0025 to 2.5 mg./kg. Intraperitoneal dosages of 25 10-30 mg./kg. of trans - dl - 5 - n - propyl -
4,4a,5,6,7,8,8a,9 - octahydro - pyrrolo - [3,4-g] -quinoline dihydrochloride resulted in no deaths, but dosages of 100-300 mg./kg. were fatal, incidating an LDm in the range 30-100 mg./kg.

Claims (1)

  1. 30 CLAIMS
    1. A compound of the general formula
    35
    A J"-U
    /
    40 wherein
    FT isH or C,-^ alkyl;
    R' is C,-C3 alkyl or allyl; and
    R' is H or CH2X wherein X is CN, CONH2, SCH3, S02CH3, or OCH3; and 45 the pharmaceutically-acceptable acid addition salts thereof.
    2. A compound of claim 1 in which R1 is H, R2 is C,-C3 alkyl, and R3 is H.
    3. trans - dl - 5 - n - Propyl - 4,4a,5,6,7,8,8a,9 -50 octahydro - 2H - pyrrolo [3,4-g] quinoline.
    4. trans - dl - 5 - Methyl - 4,4a5,6,7,8,8a,9 -octahydro - 2H - pyrrolo [3,4-g] quinoline.
    5. trans - dl - 5n - Propyl - 7 - methylmercapto-methyl - 4,4a,5,6,7,8,8a,9 - octahydro - 2H - pyrrolo
    55 [3,4-g] quinoline.
    6. A compound of the formula
    60
    65
    Ic wherein R1 is H or (C,-C3)alkyl-CO;
    R2 is H, benzyl or C,-^ alkyl; and R3 is H, COO(C,-C3)alkyl, COOH, or CH2X1 wherein, 70 X1 is OH, CI, 0S02 (C,-C3) alkyl, 0S02tolyl, or 0S02phenyl;
    with the proviso that both R1 and R3 can not be H , when R2 is C,-C3 alkyl; and their salts.
    7. trans - dl - 4,4a,5,6,7,8,8a,9 - Octahydro - 2H -pyrrolo [3,4-g] quinoline.
    8. trans - dl -1 - Acetyl - 5n - propyl - 7 - ethoxycarbonyl - 4,4a,5,6,7,8,8a,9 - octahydropyrrolo [3,4-g] quinoline.
    9. A process for preparing a compound of the general formula
    75
    80
    85
    90
    ,(> ..A'
    wherein R1 is H orCrC3 alkyl;
    R2 is C,-C3 alkyl or allyl;
    R3 is H or CH2X wherein X is CN, C0NH2, SCH3, 95 S02CH3, orOCH3; and the pharmaceutically-acceptable acid addition salts thereof;
    which comprises reacting a compound of the formula
    100
    105
    />
    ■JLJ
    Id wherein
    R1 is (Ci-C3)alkyl-CO;
    110 R2 is H, C,-C3 alkyl, or allyl;
    R3 is H or CH2Y;
    Y is CI, Br, 0S02phenyl, O-tosyl, orS02{C,-C3)
    alkyl;
    with base to provide the compounds of formula I 115 wherein R' is H;
    optionally followed by reacting with an alkyl halide to obtain the compounds offormula I wherein R' is C,-C3 alkyl;
    where R2 is H followed by reacting with an alkyl or" 120 allyl halide or reductive alkylation with an appropriate aldehyde and metal hydride to obtain the compounds offormula I where R2 is C,-C3 alkyl or allyl; 5
    followed by reacting the compound offormula Id where R3 is CH2Y with sodium methylate, methyl-125 mercaptan sodium salt, sodium cyanide, sodium methanesulfinate, to obtain the compounds offormula I where R3 is CH2X where X is CN, SCH3,
    S02CH3, or 0CH3; and optionally followed by hydration of the com-130 pounds offormula I where Ft3 is CH2CN to obtain the
    13
    GB 2 040 917 A
    13
    compounds offormula I where R3 is CH2CONH2.
    10. A compound offormula I as defined in claim 1 whenever prepared by the process ofclaim9oran obvious chemical equivalent thereof. 5 11. A pharmaceutical composition which comprises a carrier and as active ingredient a compound offormula I as defined in any of claims 1 to 5.
    12. A method of inhibiting the secretion of prolactin in a mammal which comprises administering a
    10 compound offormula I as defined in any of claims 1 to 5 to said mammal.
    13. A method of treating Parkinsonism in a mammal which comprises administerating a compound offormula I as defined in any of claims 1 to 5
    15 to said mammal.
    Printed for Her Majesty's Stationery Office by The Tweeddale Press Ltd., Berwick-upon-Tweed, 1980.
    Published at the Patent Office, 25 Southampton Buildings, London, WC2A1AY, from which copies may be obtained.
GB7922532A 1979-01-22 1979-06-28 Octahydro-2h - pyrrolo (3,4-g) quinolines Expired GB2040917B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US506279A 1979-01-22 1979-01-22
US06/031,642 US4235909A (en) 1979-04-19 1979-04-19 Octahydro-2H-pyrrolo[3,4-g]quinolines

Publications (2)

Publication Number Publication Date
GB2040917A true GB2040917A (en) 1980-09-03
GB2040917B GB2040917B (en) 1983-01-06

Family

ID=26673871

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7922532A Expired GB2040917B (en) 1979-01-22 1979-06-28 Octahydro-2h - pyrrolo (3,4-g) quinolines

Country Status (25)

Country Link
EP (1) EP0013788B1 (en)
JP (1) JPS55100385A (en)
AR (1) AR225012A1 (en)
AT (1) AT365189B (en)
AU (1) AU528035B2 (en)
BE (1) BE877328A (en)
CA (1) CA1131227A (en)
CH (2) CH641801A5 (en)
DD (1) DD144668A5 (en)
DE (1) DE2965277D1 (en)
DK (1) DK268979A (en)
ES (1) ES482084A1 (en)
FI (1) FI65248C (en)
FR (2) FR2446833A1 (en)
GB (1) GB2040917B (en)
IE (1) IE48295B1 (en)
IL (1) IL57665A (en)
LU (1) LU81440A1 (en)
NZ (1) NZ190834A (en)
PH (2) PH15118A (en)
PL (1) PL125785B1 (en)
PT (1) PT69828A (en)
RO (1) RO77442A (en)
SU (1) SU1113006A3 (en)
ZA (1) ZA793244B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65269A0 (en) * 1981-03-24 1982-05-31 Lilly Co Eli 6-substituted hexahydroindazolo or hexahydroisoindolo isoquinolines
DE3373468D1 (en) * 1983-06-03 1987-10-15 Lilly Co Eli TRANS-DL-1-ALKYL-6-ALKOXYOCTAHYDROQUINOLINES
IL73001A0 (en) * 1983-09-26 1984-12-31 Lilly Co Eli Improvements in and relating to 6-oxodecahydroquinolines
US4595754A (en) * 1985-03-04 1986-06-17 Eli Lilly And Company Process for preparing cis N-alkylperhydroquinolines
TW200904817A (en) * 2007-06-19 2009-02-01 Astrazeneca Ab Compounds and uses thereof
TWI537274B (en) 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 Novel octahydrothienoquinoline derivatives, pharmaceutical compositions containing the same, and their uses

Also Published As

Publication number Publication date
PT69828A (en) 1979-07-01
JPS6233233B2 (en) 1987-07-20
CH643258A5 (en) 1984-05-30
FI65248B (en) 1983-12-30
FR2446833B1 (en) 1982-03-05
RO77442A (en) 1982-10-26
AT365189B (en) 1981-12-28
ES482084A1 (en) 1980-08-01
AU4844479A (en) 1980-07-31
PL125785B1 (en) 1983-06-30
FR2446835A1 (en) 1980-08-14
PH16181A (en) 1983-07-25
IL57665A (en) 1982-11-30
DE2965277D1 (en) 1983-06-01
AR225012A1 (en) 1982-02-15
EP0013788B1 (en) 1983-04-27
ZA793244B (en) 1981-02-25
PH15118A (en) 1982-08-10
CH641801A5 (en) 1984-03-15
FI65248C (en) 1984-04-10
NZ190834A (en) 1984-07-06
ATA452579A (en) 1981-05-15
FR2446833A1 (en) 1980-08-14
BE877328A (en) 1979-12-28
SU1113006A3 (en) 1984-09-07
CA1131227A (en) 1982-09-07
LU81440A1 (en) 1979-09-12
PL216721A1 (en) 1980-06-16
IE791210L (en) 1980-10-19
FI792047A (en) 1980-07-23
AU528035B2 (en) 1983-04-14
EP0013788A1 (en) 1980-08-06
DD144668A5 (en) 1980-10-29
JPS55100385A (en) 1980-07-31
IL57665A0 (en) 1979-10-31
GB2040917B (en) 1983-01-06
IE48295B1 (en) 1984-11-28
DK268979A (en) 1980-07-23
FR2446835B1 (en) 1982-04-23

Similar Documents

Publication Publication Date Title
EP0013787B1 (en) Octahydro pyrazolo (3,4-g)quinolines, process for their preparation and pharmaceutical compositions containing them
US4235909A (en) Octahydro-2H-pyrrolo[3,4-g]quinolines
US4110339A (en) 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
US4501890A (en) Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines
US4230861A (en) 1-And/or 7-substituted-6-hydroxy (or oxo)-3-decahydroquinoline carboxylic acids
EP0026671A1 (en) Novel ergoline derivatives, compositions containing them, their preparation and use as pharmaceuticals
GB2040917A (en) Octahydro-2h - pyrrolo (3,4-g) quinolines
IE42198B1 (en) Ergoline derivatives
US4367231A (en) Method of using octahydro pyrazolo[3,4-g]quinolines
US4311844A (en) Octahydro-2H-pyrrolo[3,4,-g]quinolines
US4282362A (en) Octahydro-2H-pyrrolo[3,4-g]quinolines
KR880001430B1 (en) Octahydro-oxazolo (4,5-g) quinoling derivatives
US4235776A (en) Tetrahydro-2H-benzo[c]pyrroles
EP0061341B1 (en) 6-substituted hexahydroindazolo isoquinolines
CA1145750A (en) Octahydro-2h-pyrrolo (3,4,-g) quinolines
US4264622A (en) Tetrahydro-2H-benzo[c]pyrroles to inhibit prolactin secretion
KR830000586B1 (en) Method for preparing octahydro-2H-pyrrolo [3, 4-g] quinoline
EP0014792B1 (en) Tetrahydro-2h-benzo(c)pyrroles, their preparation, pharmaceutical compositions containing them and the compounds for use as therapeuticals
US4599339A (en) Use of pyrimido[4,5-g]quinolines in treating parkinsonism
HU180234B (en) Process for producing oktahydro-pyrasolo-aracket-3,4-g-bracket closed-quinolines
CA1136629A (en) Octahydro pyrazolo (3,4,-g) quinolines
EP0209983A1 (en) Dialkylaminotetrahydroquinazoline
IE48395B1 (en) Octahydro pyrazolo(3,4-g)quinolines

Legal Events

Date Code Title Description
7732 Case decided by the comptroller ** patent revoked (sect. 73(2)/1977)